The Non-Steroidal Anti-Inflammatory Drugs Market is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of chronic pain and inflammation such as migraine, arthritis, ophthalmic diseases, and others with the increasing research & developmental activities in the non-steroidal anti-inflammatory drugs across the globe.
The non-steroidal anti-inflammatory drugs market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030. The non-steroidal anti-inflammatory drugs market is observing substantial market growth due to the growing burden of chronic pain and inflammation diseases such as arthritis, migraine, and others. Further, the increasing geriatric population base prone to chronic pain, inflammation, other related diseases and the rising preference for NSAIDs over different classes of pain relievers owing to the fewer side effects offered by the class will aid in surging the demand for non-steroidal anti-inflammatory drugs. Additionally, the increasing drug approvals and launches, increasing research and development activities will increase the demand for nonsteroidal anti-inflammatory drugs in the market. Therefore, the market for non-steroidal anti-inflammatory drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
NSAIDs are the most commonly prescribed drugs for the treatment of mild to severe pain. The American Academy of Family Physicians recommends the use of ibuprofen and naproxen as the first line of treatment for mild to moderate pain. Thus, such positive recommendations are expected to boost the NSAIDs market growth during the forecast period from 2024 to 2030.
Moreover, the increasing research on selective cyclooxygenase-2 (COX-2) inhibitors forms one of the important factors driving the NSAIDS market. Current NSAIDs, such as diclofenac and ibuprofen, not only inhibit COX-2 activity but also COX-1 activity, resulting in undesirable side effects. Selective COX-2 inhibitors continue to be a difficult and ambiguous area for pharmaceutical companies. Celebrex, manufactured by Pfizer, is currently the only COX-2 inhibitor commercially available in the United States. However, many pharmaceutical behemoths are now investing heavily in the development of new COX-2 inhibitors for the treatment of pain and inflammation. For example, Crystal Genomics is currently running a phase 3 clinical trial for CG100649, a dual COX-2 and carbonic anhydrase (CA) inhibitor for the treatment of osteoarthritis.
The increasing number of NSAID launches and approvals in the market will also increase its demand in the upcoming years. For instance, in May 2021, Heron Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) approved Zynrelef, an extended-release dual-acting local anesthetic of bupivacaine and meloxicam for pain management.
Therefore, all the factors stated above collectively are expected to drive the overall non-steroidal anti-inflammatory drugs market throughout the forecast period from 2024 to 2030.
However, the high cost of drug development, side effects associated with NSAIDs, and the timeline of stringent regulatory approval process may prove to be challenging factors for the non-steroidal anti-inflammatory drugs market growth.
In the Indication segment of the non-steroidal anti-inflammatory drugs market, the arthritis category is expected to have a significant revenue share in the year 2023. This is primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches, strategic investments, and other activities by key players related to the segment will support in driving its market during the forecast period.
For instance, as per the Global RA Network 2021, more than 350 million people had arthritis, in 2021, globally. Further, according to the World Health Organization (2021), more than 14 million people had rheumatoid arthritis in 2021 globally.
Thus, the rising prevalence of different types of arthritis around the globe is ultimately expected to lead to an increased demand for arthritis-managing NSAIDs.
Moreover, the presence of huge arthritis-treating NSAIDs in the pipeline is expected to create a positive outlook for the market. For instance, Overseas Pharmaceuticals, Ltd., is conducting a Phase III efficacy study with the title 'A randomized, double-blind, parallel-arm study comparing the efficacy of investigational product "Ibuprofen Modified-Release Tablets 800 mg" and placebo in patients with chronic pain related to osteoarthritis of the knee.' The primary objective is to determine the analgesic efficacy of orally administered IBUMR in patients with osteoarthritis (OA) of the knee. Thus, such research and development activities will increase the chances of the availability of various drugs in the market as the demand for NSAIDs in the treatment of arthritis is rising substantially.
Further, various other strategic steps by the key players in the market will help in increasing demand for NSAIDs. For instance, in January 2021, the U.S. Food and Drug Administration approved a generic version of Pfizer‘s Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The generic drug is also indicated to treat osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea.
Therefore, owing to all the above-mentioned factors, the demand for arthritis drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the non-steroidal anti-inflammatory drugs market during the forecast period.
According to the Centre for Disease Control and Prevention (2024), it was stated that in 2022, the age-adjusted prevalence of diagnosed arthritis among adults aged 18 and older was 18.9%. The prevalence was higher among women, at 21.5%, compared to men, at 16.1%. The incidence of arthritis increased with age, starting from 3.6% in adults aged between 18 and 34 and rising significantly to 53.9% in individuals aged 75 and older in the US. Also, by the year 2040, an estimated 78.4 million US adults aged 18 years and older will be diagnosed with arthritis.
The data provided by the Arthritis Society Canada, 2021, stated that in 2021, nearly 6 million people were living with arthritis in Canada. The number is expected to rise to 9 million in 2040.
According to the American Headache Society (2022), stated that 37 million people were living with migraine in the US. This substantial prevalence of migraine highlights a significant and growing market for nonsteroidal anti-inflammatory drugs. Additionally, with the growing awareness and diagnosis of migraines, healthcare providers may prescribe NSAIDs more frequently as part of a comprehensive pain management plan. This expanding market presents an opportunity for further research and development of more advanced NSAID formulations in North America.
Thus, the rising prevalence of chronic pain and inflammation related disorders such as migraine, arthritis, and others will propel the demand for non-steroidal anti-inflammatory drugs during the forecast period.
Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in August 2021, Dr. Reddy's Laboratories Ltd, announced the re-launch of over the counter (OTC) Naproxen Sodium Tablets USP, 220 mg, in the US market, as approved by the US Food and Drug Administration (USFDA).
Moreover, the market players in the country are continuously focusing on the development of novel drugs to tackle these indications using NSAIDs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in March 2024, Endo International plc a leading key player in the US announced, that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America non-steroidal anti-inflammatory drugs market.
This product will be delivered within 2 business days.
The non-steroidal anti-inflammatory drugs market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030. The non-steroidal anti-inflammatory drugs market is observing substantial market growth due to the growing burden of chronic pain and inflammation diseases such as arthritis, migraine, and others. Further, the increasing geriatric population base prone to chronic pain, inflammation, other related diseases and the rising preference for NSAIDs over different classes of pain relievers owing to the fewer side effects offered by the class will aid in surging the demand for non-steroidal anti-inflammatory drugs. Additionally, the increasing drug approvals and launches, increasing research and development activities will increase the demand for nonsteroidal anti-inflammatory drugs in the market. Therefore, the market for non-steroidal anti-inflammatory drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
Non-Steroidal Anti-Inflammatory Drugs Market Dynamics:
According to the World Health Organization (2023), in 2020, there were 619 million cases of lower back pain (LBP) and it is projected that the number of LBP cases will rise to 843 million by 2050. As per data by the European Pain Federation (2023), it was stated that 740 million people globally experience an episode of severe pain at some point in their lives on average. For approximately 20% of these individuals, the pain persists for longer than three months, thereby categorizing it as chronic pain.NSAIDs are the most commonly prescribed drugs for the treatment of mild to severe pain. The American Academy of Family Physicians recommends the use of ibuprofen and naproxen as the first line of treatment for mild to moderate pain. Thus, such positive recommendations are expected to boost the NSAIDs market growth during the forecast period from 2024 to 2030.
Moreover, the increasing research on selective cyclooxygenase-2 (COX-2) inhibitors forms one of the important factors driving the NSAIDS market. Current NSAIDs, such as diclofenac and ibuprofen, not only inhibit COX-2 activity but also COX-1 activity, resulting in undesirable side effects. Selective COX-2 inhibitors continue to be a difficult and ambiguous area for pharmaceutical companies. Celebrex, manufactured by Pfizer, is currently the only COX-2 inhibitor commercially available in the United States. However, many pharmaceutical behemoths are now investing heavily in the development of new COX-2 inhibitors for the treatment of pain and inflammation. For example, Crystal Genomics is currently running a phase 3 clinical trial for CG100649, a dual COX-2 and carbonic anhydrase (CA) inhibitor for the treatment of osteoarthritis.
The increasing number of NSAID launches and approvals in the market will also increase its demand in the upcoming years. For instance, in May 2021, Heron Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) approved Zynrelef, an extended-release dual-acting local anesthetic of bupivacaine and meloxicam for pain management.
Therefore, all the factors stated above collectively are expected to drive the overall non-steroidal anti-inflammatory drugs market throughout the forecast period from 2024 to 2030.
However, the high cost of drug development, side effects associated with NSAIDs, and the timeline of stringent regulatory approval process may prove to be challenging factors for the non-steroidal anti-inflammatory drugs market growth.
Non-Steroidal Anti-Inflammatory Drugs Market Segment Analysis:
Non-Steroidal Anti-Inflammatory Drugs Market by Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the Indication segment of the non-steroidal anti-inflammatory drugs market, the arthritis category is expected to have a significant revenue share in the year 2023. This is primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches, strategic investments, and other activities by key players related to the segment will support in driving its market during the forecast period.
For instance, as per the Global RA Network 2021, more than 350 million people had arthritis, in 2021, globally. Further, according to the World Health Organization (2021), more than 14 million people had rheumatoid arthritis in 2021 globally.
Thus, the rising prevalence of different types of arthritis around the globe is ultimately expected to lead to an increased demand for arthritis-managing NSAIDs.
Moreover, the presence of huge arthritis-treating NSAIDs in the pipeline is expected to create a positive outlook for the market. For instance, Overseas Pharmaceuticals, Ltd., is conducting a Phase III efficacy study with the title 'A randomized, double-blind, parallel-arm study comparing the efficacy of investigational product "Ibuprofen Modified-Release Tablets 800 mg" and placebo in patients with chronic pain related to osteoarthritis of the knee.' The primary objective is to determine the analgesic efficacy of orally administered IBUMR in patients with osteoarthritis (OA) of the knee. Thus, such research and development activities will increase the chances of the availability of various drugs in the market as the demand for NSAIDs in the treatment of arthritis is rising substantially.
Further, various other strategic steps by the key players in the market will help in increasing demand for NSAIDs. For instance, in January 2021, the U.S. Food and Drug Administration approved a generic version of Pfizer‘s Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The generic drug is also indicated to treat osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea.
Therefore, owing to all the above-mentioned factors, the demand for arthritis drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the non-steroidal anti-inflammatory drugs market during the forecast period.
North America is expected to dominate the overall non-steroidal anti-inflammatory drugs market:
Among all the regions, North America is estimated to amass the largest revenue share in the non-steroidal anti-inflammatory drugs market in the year 2023. This can be ascribed to the increasing demand for non-steroidal anti-inflammatory drugs in the region owing to increasing chronic pain and rising adoption of NSAIDs in the management of headaches, migraine, toothaches, menstrual pain, and others. Further, the rising preference for NSAIDs over other classes of pain relievers, and the presence of key domicile players in the region, among others are the key factors that contribute to the growth of the non-steroidal anti-inflammatory drugs market in North America during the forecast period from 2024 to 2030.According to the Centre for Disease Control and Prevention (2024), it was stated that in 2022, the age-adjusted prevalence of diagnosed arthritis among adults aged 18 and older was 18.9%. The prevalence was higher among women, at 21.5%, compared to men, at 16.1%. The incidence of arthritis increased with age, starting from 3.6% in adults aged between 18 and 34 and rising significantly to 53.9% in individuals aged 75 and older in the US. Also, by the year 2040, an estimated 78.4 million US adults aged 18 years and older will be diagnosed with arthritis.
The data provided by the Arthritis Society Canada, 2021, stated that in 2021, nearly 6 million people were living with arthritis in Canada. The number is expected to rise to 9 million in 2040.
According to the American Headache Society (2022), stated that 37 million people were living with migraine in the US. This substantial prevalence of migraine highlights a significant and growing market for nonsteroidal anti-inflammatory drugs. Additionally, with the growing awareness and diagnosis of migraines, healthcare providers may prescribe NSAIDs more frequently as part of a comprehensive pain management plan. This expanding market presents an opportunity for further research and development of more advanced NSAID formulations in North America.
Thus, the rising prevalence of chronic pain and inflammation related disorders such as migraine, arthritis, and others will propel the demand for non-steroidal anti-inflammatory drugs during the forecast period.
Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in August 2021, Dr. Reddy's Laboratories Ltd, announced the re-launch of over the counter (OTC) Naproxen Sodium Tablets USP, 220 mg, in the US market, as approved by the US Food and Drug Administration (USFDA).
Moreover, the market players in the country are continuously focusing on the development of novel drugs to tackle these indications using NSAIDs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in March 2024, Endo International plc a leading key player in the US announced, that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America non-steroidal anti-inflammatory drugs market.
Non-Steroidal Anti-Inflammatory Drugs Market key players:
Some of the key market players operating in the Non-Steroidal Anti-Inflammatory Drugs Market include Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi, GSK plc., Heron Therapeutics, Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC., Assertio Holdings, Inc., AstraZeneca, Boehringer Ingelheim Ltd., Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Eli Lilly and Company, and others.Recent Developmental Activities in the Non-Steroidal Anti-Inflammatory Drugs Market:
- In August 2022, Strides Pharma Global Pte Ltd received approval from the US health regulator for generic naproxen sodium soft gel capsules, used to treat pain or inflammation.
- In August 2021, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA.
- In February of 2021, Strides Pharma Science Limited received approval for Ibuprofen Oral Suspension from the United States Food & Drug Administration U.S.FDA.
Key Takeaways from the Non-Steroidal Anti-Inflammatory Drugs Market Report Study
- Market size analysis for current Non-Steroidal Anti-Inflammatory Drugs Market size (2023), and market forecast for 6 years (2024 to 2030)
- Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the non-steroidal anti-inflammatory drugs market.
- Various opportunities available for the other competitors in the non-steroidal anti-inflammatory drugs market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current non-steroidal anti-inflammatory drugs market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for non-steroidal anti-inflammatory drugs market growth in the coming future?
- Non-steroidal anti-inflammatory drugs providers
- Research organizations and consulting companies
- Non-steroidal anti-inflammatory drugs-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in non-steroidal anti-inflammatory drugs
- Various manufacturers want to know more about the non-steroidal anti-inflammatory drugs market and the latest developments in the non-steroidal anti-inflammatory drugs market.
Frequently Asked Questions for the Non-Steroidal Anti-Inflammatory Drugs Market:
1. What is the non-steroidal anti-inflammatory drugs market?
The Non-steroidal anti-inflammatory drugs (NSAIDs) refer to a group of drug classes that reduces pain, decreases fever, prevents blood clots, and decreases inflammation in higher doses. NSAIDs block enzymes in the body that produce prostaglandins. Prostaglandins are a group of naturally occurring fatty acids that play a role in pain and inflammation.2. What is the market for non-steroidal anti-inflammatory drugs market?
The non-steroidal anti-inflammatory drugs market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030.3. What are the drivers for the non-steroidal anti-inflammatory drugs market?
The non-steroidal anti-inflammatory drugs market is witnessing positive market growth owing to factors such as the growing burden of chronic pain and inflammation causing diseases such as arthritis, migraine, and others, the increasing geriatric population base prone to chronic pain, rising preference for NSAIDs over other class of pain relievers, increasing research and developmental activities, and others will create an exigency for the non-steroidal anti-inflammatory drugs market during the forecast period from 2024 to 2030.4. Who are the key players operating in the non-steroidal anti-inflammatory drugs market?
Some of the key market players operating in the non-steroidal anti-inflammatory drugs market include Pfizer Inc., Johnson & Johnson Services, Inc, Bayer AG, Sanofi, GSK plc, Heron Therapeutics, Inc, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd, Reckitt Benckiser Group PLC, Assertio Holdings, Inc, AstraZeneca, Boehringer Ingelheim Ltd, Assertio Holdings, Inc, Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc, Dr. Reddy's Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc, Eli Lilly and Company, and others.5. Which region has the highest share in the non-steroidal anti-inflammatory drugs market?
Among all the regions, North America is estimated to hold a significant revenue share in the non-steroidal anti-inflammatory drugs market. This can be ascribed to the increasing demand for non-steroidal anti-inflammatory drugs among the patients in the region owing to increasing chronic pain and rising adoption of NSAIDs in headaches, migraine, toothaches, menstrual pain, and others. Further, the rising preference for NSAIDs over other classes of pain relievers, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America non-steroidal anti-inflammatory drugs market growth during the forecast period from 2024 to 2030.This product will be delivered within 2 business days.
Table of Contents
1. Non-Steroidal Anti-Inflammatory Drugs Market Report Introduction
2. Non-Steroidal Anti-Inflammatory Drugs Market Executive Summary
4. Regulatory Analysis
5. Non-Steroidal Anti-Inflammatory Drugs Market Key Factors Analysis
6. Non-Steroidal Anti-Inflammatory Drugs Market Porter’s Five Forces Analysis
7. Non-Steroidal Anti-Inflammatory Drugs Market Assessment
8. Non-Steroidal Anti-Inflammatory Drugs Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Johnson & Johnson Services, Inc
- Bayer AG
- Sanofi
- GSK plc
- Heron Therapeutics, Inc
- Strides Pharma Science Limited
- Sun Pharmaceutical Industries Ltd
- Reckitt Benckiser Group PLC
- Assertio Holdings, Inc
- AstraZeneca
- Boehringer Ingelheim Ltd
- Assertio Holdings, Inc
- Horizon Therapeutics plc
- Perrigo Company plc
- Viatris Inc
- Dr. Reddy’s Laboratories Ltd
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc
- Eli Lilly and Company
